Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Cost of Revenue (2021 - 2025)

Historic Cost of Revenue for Coeptis Therapeutics Holdings (COEPW) over the last 4 years, with Q3 2025 value amounting to $45155.0.

  • Coeptis Therapeutics Holdings' Cost of Revenue changed N/A to $45155.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $196812.0, marking a year-over-year change of. This contributed to the annual value of $15000.0 for FY2023, which is 8333.33% down from last year.
  • Per Coeptis Therapeutics Holdings' latest filing, its Cost of Revenue stood at $45155.0 for Q3 2025.
  • Coeptis Therapeutics Holdings' Cost of Revenue's 5-year high stood at $141518.0 during Q1 2021, with a 5-year trough of $300.0 in Q2 2023.
  • Moreover, its 4-year median value for Cost of Revenue was $45155.0 (2025), whereas its average is $49292.2.
  • Examining YoY changes over the last 5 years, Coeptis Therapeutics Holdings' Cost of Revenue showed a top increase of 8125.0% in 2023 and a maximum decrease of 9400.0% in 2023.
  • Over the past 4 years, Coeptis Therapeutics Holdings' Cost of Revenue (Quarter) stood at $141518.0 in 2021, then plummeted by 96.47% to $5000.0 in 2022, then surged by 200.0% to $15000.0 in 2023, then surged by 201.03% to $45155.0 in 2025.
  • Its Cost of Revenue stands at $45155.0 for Q3 2025, versus $45157.0 for Q2 2025 and $106500.0 for Q1 2025.